Lactic Acidosis in Diabetic Population: Is Metformin Implicated? Results of a Matched Case-Control Study Performed on the Type 2 Diabetes Population of Grenoble Hospital University

Table 4

Multivariate analysis with stratification variable: AKI.

Variables	⁢Patients with AKI			⁢Patients without AKI
	OR	CI 95%	value	OR	CI 95%	value
Chronic medical condition
CKD mild-moderate	0.42	[0.25–0.73]	0.002	0.33	[0.16–0.68]	0.003
CKD severe-end stage	1.82	[0.80–4.13]	0.149	1.29	[0.49–3.43]	0.607
Hepatocellular dysfunction	5.29	[2.56–10.95]	<0.001	5.17	[2.29–11.67]	<0.001
Concomitant therapies
Metformin	1.79	[1.09–2.93]	0.020	0.86	[0.48–1.55]	0.628
Iodinated CM	8.58	[3.77–19.52]	<0.001	—	—	—
Intercurrent diseases
Shock	42.06	[17.91–98.78]	<0.001	—	—	—
Severe anemia	5.83	[2.58–3.17]	<0.001	—	—	—
Acute respiratory failure	11.86	[6.79–20.74]	<0.001	12.38	[6.52–23.50]	<0.001
Acute decompensated heart failure	5.19	[2.88–9.36]	<0.001	6.29	[3.12–12.66]	<0.001
Sepsis	4.34	[2.45–7.70]	<0.001	6.87	[3.61–13.07]	<0.001